Quince Therapeutics, Inc. Net Fee Amt
Quince Therapeutics, Inc. (QNCX) had Net Fee Amt of $38.56 thousand as of 2026-07-28, per its S-3 filed 2026-07-31.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-31
- 2026-07-28: Net Fee Amt $38.56K.
- 2026-04-15: Net Fee Amt $42.61.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-28 | $38.56K S-3 · filed 2026-07-31 |
| 2026-04-15 | $42.61 S-8 · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |